BACKGROUND: Differentiated thyroid cancer (DTC) is seen in 3%-10% of individuals carrying a germline PTEN mutation. Patients with PTEN mutations are at risk for additional neoplasms as are their affected offspring. However, the frequency of PTEN mutations among DTC cases has not been systematically analyzed. The objective of this study was to determine the frequency of PTEN mutations in an unselected group of patients with DTC and to identify whether additional clinical features might indicate the need for referral for genetic counseling and possible testing. METHODS: We collected personal medical and family history information, head circumference data, and blood from 259 consecutively identified clinic-based patients with DTC, unselected for personal or family history. Individuals were categorized for diagnostic criteria for Cowden syndrome (CS) using the 2009 National Comprehensive Cancer Network (NCCN) guidelines and underwent germline PTEN mutation analysis. RESULTS: Two of the 259 patients (0.8%), with both follicular thyroid carcinoma and macrocephaly, were found to carry a germline mutation in the PTEN gene. The PTEN mutation frequency in unselected cases of follicular thyroid carcinoma was 4.8%. CONCLUSION: The frequency of germline pathogenic PTEN mutations in an unselected series of patients with DTC is relatively low, but it is enriched by considering follicular histology and macrocephaly. These results suggest that by adding head circumference to the clinical assessment, thyroid cancer specialists can more effectively identify patients needing referral for cancer genetic services.
BACKGROUND:Differentiated thyroid cancer (DTC) is seen in 3%-10% of individuals carrying a germline PTEN mutation. Patients with PTEN mutations are at risk for additional neoplasms as are their affected offspring. However, the frequency of PTEN mutations among DTC cases has not been systematically analyzed. The objective of this study was to determine the frequency of PTEN mutations in an unselected group of patients with DTC and to identify whether additional clinical features might indicate the need for referral for genetic counseling and possible testing. METHODS: We collected personal medical and family history information, head circumference data, and blood from 259 consecutively identified clinic-based patients with DTC, unselected for personal or family history. Individuals were categorized for diagnostic criteria for Cowden syndrome (CS) using the 2009 National Comprehensive Cancer Network (NCCN) guidelines and underwent germline PTEN mutation analysis. RESULTS: Two of the 259 patients (0.8%), with both follicular thyroid carcinoma and macrocephaly, were found to carry a germline mutation in the PTEN gene. The PTEN mutation frequency in unselected cases of follicular thyroid carcinoma was 4.8%. CONCLUSION: The frequency of germline pathogenic PTEN mutations in an unselected series of patients with DTC is relatively low, but it is enriched by considering follicular histology and macrocephaly. These results suggest that by adding head circumference to the clinical assessment, thyroid cancer specialists can more effectively identify patients needing referral for cancer genetic services.
Authors: M R Nelen; W C van Staveren; E A Peeters; M B Hassel; R J Gorlin; H Hamm; C F Lindboe; J P Fryns; R H Sijmons; D G Woods; E C Mariman; G W Padberg; H Kremer Journal: Hum Mol Genet Date: 1997-08 Impact factor: 6.150
Authors: D J Marsh; V Coulon; K L Lunetta; P Rocca-Serra; P L Dahia; Z Zheng; D Liaw; S Caron; B Duboué; A Y Lin; A L Richardson; J M Bonnetblanc; J M Bressieux; A Cabarrot-Moreau; A Chompret; L Demange; R A Eeles; A M Yahanda; E R Fearon; J P Fricker; R J Gorlin; S V Hodgson; S Huson; D Lacombe; C Eng Journal: Hum Mol Genet Date: 1998-03 Impact factor: 6.150
Authors: D Liaw; D J Marsh; J Li; P L Dahia; S I Wang; Z Zheng; S Bose; K M Call; H C Tsou; M Peacocke; C Eng; R Parsons Journal: Nat Genet Date: 1997-05 Impact factor: 38.330
Authors: D J Marsh; J B Kum; K L Lunetta; M J Bennett; R J Gorlin; S F Ahmed; J Bodurtha; C Crowe; M A Curtis; M Dasouki; T Dunn; H Feit; M T Geraghty; J M Graham; S V Hodgson; A Hunter; B R Korf; D Manchester; S Miesfeldt; V A Murday; K L Nathanson; M Parisi; B Pober; C Romano; C Eng Journal: Hum Mol Genet Date: 1999-08 Impact factor: 6.150
Authors: M R Nelen; G W Padberg; E A Peeters; A Y Lin; B van den Helm; R R Frants; V Coulon; A M Goldstein; M M van Reen; D F Easton; R A Eeles; S Hodgsen; J J Mulvihill; V A Murday; M A Tucker; E C Mariman; T M Starink; B A Ponder; H H Ropers; H Kremer; M Longy; C Eng Journal: Nat Genet Date: 1996-05 Impact factor: 38.330
Authors: D J Marsh; P L Dahia; S Caron; J B Kum; I M Frayling; I P Tomlinson; K S Hughes; R A Eeles; S V Hodgson; V A Murday; R Houlston; C Eng Journal: J Med Genet Date: 1998-11 Impact factor: 6.318
Authors: Gary L Francis; Steven G Waguespack; Andrew J Bauer; Peter Angelos; Salvatore Benvenga; Janete M Cerutti; Catherine A Dinauer; Jill Hamilton; Ian D Hay; Markus Luster; Marguerite T Parisi; Marianna Rachmiel; Geoffrey B Thompson; Shunichi Yamashita Journal: Thyroid Date: 2015-07 Impact factor: 6.568
Authors: S Adeleh Razavi; Mohammad Hossein Modarressi; Parichehr Yaghmaei; S Mohammad Tavangar; Mehdi Hedayati Journal: Endocrine Date: 2017-07-28 Impact factor: 3.633
Authors: Daphne R Pringle; Zhirong Yin; Audrey A Lee; Parmeet K Manchanda; Lianbo Yu; Alfred F Parlow; David Jarjoura; Krista M D La Perle; Lawrence S Kirschner Journal: Endocr Relat Cancer Date: 2012-05-24 Impact factor: 5.678
Authors: Emily Hughes Douglas; Anthony Rhoads; Alexandra Thomas; Joseph Aloi; Jonathan Suhl; Thomas Lycan; Jacob Oleson; Kristin M Conway; Joanna Klubo-Gwiezdzinska; Charles F Lynch; Paul A Romitti Journal: Thyroid Date: 2020-06-10 Impact factor: 6.568